OBJECTIVE: The objective of this study is to determine whether the amniotic fluid (AF) concentration of soluble CXCR3 and its ligands CXCL9 and CXCL10 changes in patients whose placentas show evidence of chronic chorioamnionitis or other placental lesions consistent with maternal anti-fetal rejection. METHODS: This retrospective case-control study included 425 women with (1) preterm delivery (n=92); (2) term in labor (n=68); and (3) term not in labor (n=265). Amniotic fluid CXCR3, CXCL9 and CXCL10 concentrations were determined by ELISA. RESULTS: (1) Amniotic fluid concentrations of CXCR3 and its ligands CXCL9 and CXCL10 are higher in patients with preterm labor and maternal anti-fetal rejection lesions than in those without these lesions [CXCR3: preterm labor and delivery with maternal anti-fetal rejection placental lesions (median, 17.24 ng/mL; IQR, 6.79-26.68) vs. preterm labor and delivery without these placental lesions (median 8.79 ng/mL; IQR, 4.98-14.7; P=0.028)]; (2) patients with preterm labor and chronic chorioamnionitis had higher AF concentrations of CXCL9 and CXCL10, but not CXCR3, than those without this lesion [CXCR3: preterm labor with chronic chorioamnionitis (median, 17.02 ng/mL; IQR, 5.57-26.68) vs. preterm labor without chronic chorioamnionitis (median, 10.37 ng/mL; IQR 5.01-17.81; P=0.283)]; (3) patients with preterm labor had a significantly higher AF concentration of CXCR3 than those in labor at term regardless of the presence or absence of placental lesions. CONCLUSION: Our findings support a role for maternal anti-fetal rejection in a subset of patients with preterm labor.
OBJECTIVE: The objective of this study is to determine whether the amniotic fluid (AF) concentration of soluble CXCR3 and its ligands CXCL9 and CXCL10 changes in patients whose placentas show evidence of chronic chorioamnionitis or other placental lesions consistent with maternal anti-fetal rejection. METHODS: This retrospective case-control study included 425 women with (1) preterm delivery (n=92); (2) term in labor (n=68); and (3) term not in labor (n=265). Amniotic fluid CXCR3, CXCL9 and CXCL10 concentrations were determined by ELISA. RESULTS: (1) Amniotic fluid concentrations of CXCR3 and its ligands CXCL9 and CXCL10 are higher in patients with preterm labor and maternal anti-fetal rejection lesions than in those without these lesions [CXCR3: preterm labor and delivery with maternal anti-fetal rejection placental lesions (median, 17.24 ng/mL; IQR, 6.79-26.68) vs. preterm labor and delivery without these placental lesions (median 8.79 ng/mL; IQR, 4.98-14.7; P=0.028)]; (2) patients with preterm labor and chronic chorioamnionitis had higher AF concentrations of CXCL9 and CXCL10, but not CXCR3, than those without this lesion [CXCR3: preterm labor with chronic chorioamnionitis (median, 17.02 ng/mL; IQR, 5.57-26.68) vs. preterm labor without chronic chorioamnionitis (median, 10.37 ng/mL; IQR 5.01-17.81; P=0.283)]; (3) patients with preterm labor had a significantly higher AF concentration of CXCR3 than those in labor at term regardless of the presence or absence of placental lesions. CONCLUSION: Our findings support a role for maternal anti-fetal rejection in a subset of patients with preterm labor.
Authors: Elena Lazzeri; Mario Rotondi; Benedetta Mazzinghi; Laura Lasagni; Andrea Buonamano; Alberto Rosati; Fabio Pradella; Vittorio Fossombroni; Giorgio La Villa; Mauro Gacci; Elisabetta Bertoni; Mario Serio; Maurizio Salvadori; Paola Romagnani Journal: Transplantation Date: 2005-05-15 Impact factor: 4.939
Authors: Joanne E Croudace; Charlotte F Inman; Ben E Abbotts; Sandeep Nagra; Jane Nunnick; Prem Mahendra; Charles Craddock; Ram Malladi; Paul A H Moss Journal: Blood Date: 2012-09-25 Impact factor: 22.113
Authors: Katrien Van Raemdonck; Philippe E Van den Steen; Sandra Liekens; Jo Van Damme; Sofie Struyf Journal: Cytokine Growth Factor Rev Date: 2014-11-22 Impact factor: 7.638
Authors: Inass Osman; Anne Young; Marie Anne Ledingham; Andrew J Thomson; Fiona Jordan; Ian A Greer; Jane E Norman Journal: Mol Hum Reprod Date: 2003-01 Impact factor: 4.025
Authors: Margarida Lima; Magdalena Leander; Marlene Santos; Ana Helena Santos; Catarina Lau; Maria Luís Queirós; Marta Gonçalves; Sónia Fonseca; João Moura; Maria Dos Anjos Teixeira; Alberto Orfao Journal: J Immunol Res Date: 2015-10-12 Impact factor: 4.818
Authors: Elizabeth Ann L Enninga; Patrick Raber; Reade A Quinton; Rodrigo Ruano; Nadia Ikumi; Clive M Gray; Erica L Johnson; Rana Chakraborty; Sarah E Kerr Journal: J Immunol Date: 2020-04-22 Impact factor: 5.422
Authors: Violetta Florova; Roberto Romero; Adi L Tarca; Jose Galaz; Kenichiro Motomura; Madison M Ahmad; Chaur-Dong Hsu; Richard Hsu; Anna Tong; Jacques Ravel; Kevin R Theis; Nardhy Gomez-Lopez Journal: Cytokine Date: 2020-10-07 Impact factor: 3.861
Authors: Robert Para; Roberto Romero; Derek Miller; Jose Galaz; Bogdan Done; Azam Peyvandipour; Meyer Gershater; Li Tao; Kenichiro Motomura; Douglas M Ruden; Jenna Isherwood; Eunjung Jung; Tomi Kanninen; Roger Pique-Regi; Adi L Tarca; Nardhy Gomez-Lopez Journal: Immunohorizons Date: 2021-09-14
Authors: Nardhy Gomez-Lopez; Roberto Romero; Sonia S Hassan; Gaurav Bhatti; Stanley M Berry; Juan Pedro Kusanovic; Percy Pacora; Adi L Tarca Journal: Front Immunol Date: 2019-12-17 Impact factor: 7.561